INTRAVITREAL METHOTREXATE IN VEMURAFENIB-INDUCED UVEITIS.
Dugauquier A, Awada AH, Motulsky E, Kisma N.
Retin Cases Brief Rep · journal article; case reports · DOI 10.1097/icb.0000000000001419 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för vemurafenib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
32 hitsVemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
Evseev D, Osipova D, Kalinina I, Raykina E, Ignatova A, Lyudovskikh E, Baidildina D, Popov A, Zhogov V, Semchenkova A, Litvin E, Kotskaya N, Cherniak E, Voronin K, Burtsev E, Bronin G, Vlasova I, Purbueva B, Fink O, Pristanskova E, Dzhukaeva I, Erega E, Novichkova G, Maschan A, Maschan M.
Blood Adv · research support, non-u.s. gov't; research-article; journal article · DOI 10.1182/bloodadvances.2022009067Retraction and republication-Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Editors of The Lancet Oncology.
Lancet Oncol · journal article; retraction notice · DOI 10.1016/s1470-2045(23)00327-3Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Dummer R, Queirolo P, Gerard Duhard P, Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA, Chiarion-Sileni V, Pronzato P, Spagnolo F, Mujika Eizmendi K, Liszkay G, de la Cruz Merino L, Tawbi H.
Lancet Oncol · research support, non-u.s. gov't; journal article · DOI 10.1016/s1470-2045(23)00334-0Vemurafenib Inhibits Acute and Chronic Enterovirus Infection by Affecting Cellular Kinase Phosphatidylinositol 4-Kinase Type IIIβ.
Laajala M, Zwaagstra M, Martikainen M, Nekoua MP, Benkahla M, Sane F, Gervais E, Campagnola G, Honkimaa A, Sioofy-Khojine AB, Hyöty H, Ojha R, Bailliot M, Balistreri G, Peersen O, Hober D, Van Kuppeveld F, Marjomäki V.
Microbiol Spectr · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1128/spectrum.00552-23In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors.
Żołek T, Mazurek A, Grudzinski IP.
Molecules · research-article; journal article · DOI 10.3390/molecules28135273Melanoma cells with acquired resistance to vemurafenib have decreased autophagic flux and display enhanced ability to transfer resistance.
Pérez CN, Falcón CR, Mons JD, Orlandi FC, Sangiacomo M, Fernandez-Muñoz JM, Guerrero M, Benito PG, Colombo MI, Zoppino FCM, Alvarez SE.
Biochim Biophys Acta Mol Basis Dis · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbadis.2023.166801Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance.
Peng J, Lin Z, Chen W, Ruan J, Deng F, Yao L, Rao M, Xiong X, Xu S, Zhang X, Liu X, Sun X.
Heliyon · research-article; journal article · DOI 10.1016/j.heliyon.2023.e17714Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer.
Ma W, Tian M, Hu L, Ruan X, Zhang W, Zheng X, Gao M.
J Cancer · research-article; journal article · DOI 10.7150/jca.83853Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone.
Zhou H, Li XF, Chen MJ, Cai LL.
Open Life Sci · letter; journal article · DOI 10.1515/biol-2022-0606Vemurafenib improves muscle histopathology in a mouse model of LAMA2-related congenital muscular dystrophy.
Oliveira-Santos A, Dagda M, Wittmann J, Smalley R, Burkin DJ.
Dis Model Mech · research support, non-u.s. gov't; research-article; journal article · DOI 10.1242/dmm.049916COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
Dummer R, Flaherty KT, Robert C, Arance A, B de Groot JW, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Schadendorf D, Yamazaki N, Pietro AD, Cantey-Kiser J, Edwards M, Ascierto PA.
Future Oncol · comparative study; randomized controlled trial; journal article · DOI 10.2217/fon-2022-1258Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib.
Car I, Dittmann A, Klobučar M, Grbčić P, Kraljević Pavelić S, Sedić M.
Biology (Basel) · research-article; journal article · DOI 10.3390/biology12040608Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.
Piejko K, Cybulska-Stopa B, Ziętek M, Dziura R, Galus Ł, Kempa-Kamińska N, Ziółkowska B, Rutkowska E, Kopciński T, Kubiatowski T, Bal W, Suwiński R, Mackiewicz J, Kamińska-Winciorek G, Czarnecka AM, Rutkowski P.
Target Oncol · research-article; journal article · DOI 10.1007/s11523-023-00954-wTargeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer.
Lang M, Longerich T, Anamaterou C.
Thyroid Res · journal article; case-report · DOI 10.1186/s13044-023-00147-7Vemurafenib and Dabrafenib Downregulates RIPK4 Level.
Madej E, Brożyna AA, Adamczyk A, Wronski N, Harazin-Lechowska A, Muzyk A, Makuch K, Markiewicz M, Rys J, Wolnicka-Glubisz A.
Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers15030918Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib.
Johnson AE, Raju AR, Jacob A, Hildebrandt GC.
Front Oncol · journal article; case reports; case-report · DOI 10.3389/fonc.2022.1100577Suppression of exosomal hsa_circ_0001005 eliminates the Vemurafenib resistance of melanoma.
Wang X, Cheng Q.
J Cancer Res Clin Oncol · research-article; journal article · DOI 10.1007/s00432-022-04434-yBRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis.
Garutti M, Bergnach M, Polesel J, Palmero L, Pizzichetta MA, Puglisi F.
Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers15010141Targeting ARF1-IQGAP1 interaction to suppress colorectal cancer metastasis and vemurafenib resistance.
Hu HF, Gao GB, He X, Li YY, Li YJ, Li B, Pan Y, Wang Y, He QY.
J Adv Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.jare.2022.11.006Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells.
Tabolacci C, Giordano D, Rossi S, Cordella M, D'Arcangelo D, Moschella F, D'Atri S, Biffoni M, Facchiano A, Facchiano F.
Molecules · research-article; journal article · DOI 10.3390/molecules27227800HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF<sup>V600E</sup> Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia.
Furfaro AL, Loi G, Ivaldo C, Passalacqua M, Pietra G, Mann GE, Nitti M.
Antioxidants (Basel) · research-article; journal article · DOI 10.3390/antiox11061171Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i>-mutated Urothelial Carcinoma.
Rossman P, Zabka TS, Ruple A, Tuerck D, Ramos-Vara JA, Liu L, Mohallem R, Merchant M, Franco J, Fulkerson CM, Bhide KP, Breen M, Aryal UK, Murray E, Dybdal N, Utturkar SM, Fourez LM, Enstrom AW, Dhawan D, Knapp DW.
Mol Cancer Ther · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1158/1535-7163.mct-20-0893Monitoring the Response of Skin Melanoma Cell Line (A375) to Treatment with Vemurafenib: A Pilot <i>In Vitro</i> Optical Spectroscopic Study.
Shirkavand A, Mohajerani E, Farivar S, Ataie-Fashtami L, Ghazimoradi MH.
Photobiomodul Photomed Laser Surg · journal article · DOI 10.1089/photob.2020.4887Vemurafenib
Författaruppgift saknas
Journal missing · reviewVemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae.
Ko CJ, McNiff JM, Iftner A, Iftner T, Choi JN.
J Am Acad Dermatol · letter; case reports · DOI 10.1016/j.jaad.2012.03.027Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F.
Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/0008-5472.can-11-2941Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma.
Luke JJ, Hodi FS.
Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-11-2197Vemurafenib.
Flaherty KT, Yasothan U, Kirkpatrick P.
Nat Rev Drug Discov · news · DOI 10.1038/nrd3579Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
Heakal Y, Kester M, Savage S.
Ann Pharmacother · review; journal article · DOI 10.1345/aph.1q363